| Followers | 425 |
| Posts | 20207 |
| Boards Moderated | 1 |
| Alias Born | 02/22/2010 |
Sunday, September 20, 2015 9:33:48 PM
$SNSS Vosaroxin Phase 3 VALOR Trial Results in September Issue of The Lancet Oncology
- Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
- the prespecified secondary analysis stratified by randomisation factors suggests that the addition of vosaroxin to cytarabine might be of clinical benefit to some patients with relapsed or refractory acute myeloid leukaemia.
http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00201-6/abstract
I like the chart here and worst appears priced in. 1.50 and into the gap is target
- Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
- the prespecified secondary analysis stratified by randomisation factors suggests that the addition of vosaroxin to cytarabine might be of clinical benefit to some patients with relapsed or refractory acute myeloid leukaemia.
http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00201-6/abstract
I like the chart here and worst appears priced in. 1.50 and into the gap is target
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
